Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:CYTHNASDAQ:ENLVNASDAQ:GDTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.60-2.7%$0.49$0.38▼$269.28$6.81M0.38993,827 shs506,170 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57485,828 shsN/AENLVEnlivex Therapeutics$0.95-0.4%$0.97$0.81▼$1.76$22.37M0.76128,626 shs48,328 shsGDTCCytoMed Therapeutics$2.32+0.4%$2.34$1.20▼$4.05$25.38M-0.3178,282 shs17,114 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+1.98%+27.37%+47.38%-27.18%-99.38%CYTHCyclo Therapeutics0.00%0.00%0.00%-6.43%-43.70%ENLVEnlivex Therapeutics+0.63%-2.50%-7.28%-7.28%-30.80%GDTCCytoMed Therapeutics-2.52%+10.71%-3.53%-15.45%+13.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma3.0408 of 5 stars3.50.00.00.02.71.71.9CYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics3.6392 of 5 stars3.75.00.00.03.80.81.3GDTCCytoMed Therapeutics1.9635 of 5 stars3.53.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0059,660.96% UpsideCYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideENLVEnlivex Therapeutics 3.33Buy$10.00957.08% UpsideGDTCCytoMed Therapeutics 3.00Buy$5.00115.52% UpsideCurrent Analyst Ratings BreakdownLatest AEON, GDTC, CYTH, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/24/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ACYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AGDTCCytoMed Therapeutics$69.50K365.19N/AN/A$0.78 per share2.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.123.35N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)CYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/AENLVEnlivex Therapeutics-$29.07M-$0.73N/AN/AN/AN/A-67.57%-58.45%6/13/2025 (Estimated)GDTCCytoMed Therapeutics-$3.13MN/A0.00∞N/AN/AN/AN/AN/ALatest AEON, GDTC, CYTH, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q4 2024ENLVEnlivex Therapeutics-$0.16N/AN/AN/AN/AN/A3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22CYTHCyclo TherapeuticsN/A0.170.16ENLVEnlivex TherapeuticsN/A9.719.71GDTCCytoMed Therapeutics0.0421.54N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%CYTHCyclo Therapeutics68.55%ENLVEnlivex Therapeutics1.02%GDTCCytoMed Therapeutics0.04%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%CYTHCyclo Therapeutics29.78%ENLVEnlivex Therapeutics12.28%GDTCCytoMed TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataENLVEnlivex Therapeutics7023.65 million18.78 millionOptionableGDTCCytoMed TherapeuticsN/A10.94 millionN/ANot OptionableAEON, GDTC, CYTH, and ENLV HeadlinesRecent News About These CompaniesCytoMed Therapeutics Schedules AGM for June 2025May 16, 2025 | tipranks.comCytoMed Therapeutics Reports 2024 Financial Results and Clinical ProgressMay 7, 2025 | tipranks.comCytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate UpdatesApril 28, 2025 | globenewswire.comCytoMed Therapeutics Limited Shares 2024 Accomplishments and Outlook for 2025 in Shareholder LetterFebruary 6, 2025 | quiverquant.comCytoMed Therapeutics announces Chairman's Letter to the Company's shareholdersFebruary 6, 2025 | globenewswire.comCytoMed Therapeutics Expands Leadership Amid Strategic GrowthDecember 5, 2024 | tipranks.comCytoMed Therapeutics Limited (GDTC)July 19, 2024 | finance.yahoo.comCytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid CancersJuly 17, 2024 | globenewswire.comCytoMed Therapeutics Ltd GDTCMarch 27, 2024 | morningstar.comCytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationMarch 20, 2024 | finance.yahoo.comCYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | finanznachrichten.deCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | markets.businessinsider.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairMarch 4, 2024 | globenewswire.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 15, 2023 | finance.yahoo.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | investing.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?July 11, 2023 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, GDTC, CYTH, and ENLV Company DescriptionsAEON Biopharma NASDAQ:AEON$0.60 -0.02 (-2.68%) Closing price 04:00 PM EasternExtended Trading$0.59 -0.01 (-2.39%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Enlivex Therapeutics NASDAQ:ENLV$0.95 0.00 (-0.42%) Closing price 03:59 PM EasternExtended Trading$0.95 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.CytoMed Therapeutics NASDAQ:GDTC$2.32 +0.01 (+0.43%) Closing price 03:48 PM EasternExtended Trading$2.27 -0.05 (-2.11%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
